{"id":427314,"date":"2024-01-02T04:30:39","date_gmt":"2024-01-02T09:30:39","guid":{"rendered":"https:\/\/platohealth.ai\/the-biotech-scorecard-for-the-first-quarter-17-stock-moving-events-to-watch\/"},"modified":"2024-01-02T10:00:20","modified_gmt":"2024-01-02T15:00:20","slug":"the-biotech-scorecard-for-the-first-quarter-17-stock-moving-events-to-watch","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/the-biotech-scorecard-for-the-first-quarter-17-stock-moving-events-to-watch\/","title":{"rendered":"The biotech scorecard for the first quarter: 17 stock-moving events to watch","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
<\/div>\n

H<\/span><\/span>ere is STAT\u2019s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter:<\/p>\n

In December, Vertex Pharmaceuticals<\/strong> announced results<\/a> from a mid-stage clinical trial showing its experimental, non-opioid drug reduced pain in people with diabetes who have chronic pain. This quarter, the company will read out results from Phase 3 studies of the same pain drug, called VX-548, in people with acute pain following surgery.<\/p>\n

\n

advertisement<\/p>\n<\/div>\n

The next big test of Alnylam Pharmaceuticals\u2019<\/strong> pipeline of RNA-interference medicines looms with the outcome of a Phase 3 study called HELIOS-B that is investigating vutrisiran as a treatment for ATTR-CM, a progressive disease that leads to heart failure.<\/p>\n

\n
\n
\n

\n\t\t\t\t\t\tGet unlimited access to award-winning journalism and exclusive events.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a>\n\t\t\t\t\t\t\t\t\t<\/div>\n<\/p><\/div>\n<\/p><\/div>\n